Published in AIDS Weekly, August 7th, 2006
The recent reinforcement of Viropro's management team will allow the company to focus and to set short and mid-term priorities to maximize shareholders' value.
On June 15, 2006, the company announced the signature of a binding Memorandum of Understanding (MOU) with Biochallenge, a Tunisia-based, privately held pharmaceutical company, for the development and the production of several therapeutic proteins, with potential revenues estimated at US$27 million. The final contractual agreement is expected in the following months.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.